Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 410-414

  Power, Patti ^a   Stuart, Gavin ^b   Oza, Amit ^c   Provencher, D ^d   Bentley, James R ^e   Miller Jr , Wilson H ^f   Pouliot, Jean François ^g  

^a Dr H Bliss Murphy Cancer Centre   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e Cancer Care Nova Scotia   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g Schering Plough Canada Inc   (Canada)

Author keywords

CA125; Carboplatin; Pegylated liposomal doxorubicin; Recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECCURENT CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 67651149486     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.037     Document Type: Article

References (18)

1. Markman M., Reichman B., Hakes T., Jones W., Lewis Jr. J.L., Rubin S., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 9 (1991) 1801-1805
2. du Bois I., Quinn M., Thigpen T., Vermorken J., Avall-Lundqvist E., et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16 Suppl 8 (2005) viii7-viii12
3. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delalove J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
4. O'Byrne K.J., Bliss P., Graham J.D., Gerber J., Vasey P.A., Khanna S., et al. Proc. Am. Soc. Clin. Oncol. 21 (2002) [abstract 808]
5. Gordon A.N., Tondab M., Sunc S., Rackoff W., and on behalf of the Doxil Study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 1-8
6. Ojeda B., Gonzalez-Sande L.M., Casado A., and Casado M.A. Cost-minimization analysis of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. topotecan in the treatment of patients with epithelial ovarian carcinoma in Spain. Proc. Am. Soc. Clin. Oncol. 21 (2002) [abstract 2596]
7. Ferrero J.M., Weber B., Lepille D., Orfeuvre H., Combe M., Mayer F., et al. Caelyx (Ca) and carboplatin (Pa) in patients with advanced ovarian cancer in late relapse (> 6 months) (AOCLR): a GINECO phase II trial. Proc. Am. Soc. Clin. Oncol. (2002) [abstract 828]
8. Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann. Oncol. 18 (2007) 263-268
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000) 205-216
10. Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer), 2005. http://ctep.info.nih.gov/resources/gcig/jncirustin.pdf. Accessed November 14, 2007.
11. Bast R, Rustin G. Use of CA-125 for response evaluation in ovarian cancer. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Ovarian cancer endpoints. www.fda.gov/cder/drug/cancer_endpoints/#ovarian. Accessed November 14, 2007.
12. Rustin G.J.S. Use of CA-125 to assess response to new agents in ovarian cancer. J. Clin. Oncol. 21 (2003) 187s-193s
13. du Bois A., Pfisterer J., Burchardi N., Loibl S., Huober J., Wimberger P., et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol. 107 (2007) 518-525
14. Coleman R., Gordon A., Barter J., Sun S., Rackoff W., and Herzog T. Early changes in CA 125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12 (2007) 72-78
15. Gossner G., Coleman R., Mutch D., Horowitz N., Rader J., et al. CA-125 response in patients with recurrent ovarian or peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol. Oncol. (2006) 212-218
16. Hsiao S., Chen C., Ho-Hsiung L., Hsieh C., and Wei L. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol. Oncol. 112 (2009) 35-39
17. Alberts D., Liu P., Wilczynski S., Clouser M., Lopez A., et al. Randomized trail of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (SWOG protocol S0200). Gynecol. Oncol. 108 (2008) 90-94
18. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., LeCave A., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol 24 29 (2006) 4699-4707